Sarepta Therapeutics Announces Presentations At The 19th International Congress Of The World Muscle Society
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that it will give one oral presentation and two poster presentations on data from its ongoing Phase II and preclinical trials evaluating exon-skipping therapies for the treatment of Duchenne muscular dystrophy (DMD) at the International Congress of the World Muscle Society (WMS), being held from October 7-11, 2014, in Berlin, Germany. The oral presentation will include additional detail about the 144-week, 6-minute walk test (6MWT) and safety data from the Phase IIb study of eteplirsen, as well as other information including 144-week pulmonary function test results and information on individual MIP and MEP results.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.